The quorum sensing inhibitor hamamelitannin increases antibiotic susceptibility of Staphylococcus aureus biofilms by affecting peptidoglycan biosynthesis and eDNA release by Brackman, Gilles et al.
1Scientific RepoRts | 6:20321 | DOI: 10.1038/srep20321
www.nature.com/scientificreports
The Quorum Sensing Inhibitor 
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Treatment of Staphylococcus aureus infections has become increasingly challenging due to the rapid 
emergence and dissemination of methicillin-resistant strains. In addition, S. aureus reside within 
biofilms at the site of infection. Few novel antibacterial agents have been developed in recent years and 
their bacteriostatic or bactericidal activity results in selective pressure, inevitably inducing antimicrobial 
resistance. Consequently, innovative antimicrobials with other modes of action are urgently needed. 
One alternative approach is targeting the bacterial quorum sensing (QS) system. Hamamelitannin 
(2′,5-di-O-galloyl-d-hamamelose; HAM) was previously suggested to block QS through the TraP QS 
system and was shown to increase S. aureus biofilm susceptibility towards vancomycin (VAN) although 
mechanistic insights are still lacking. In the present study we provide evidence that HAM specifically 
affects S. aureus biofilm susceptibility through the TraP receptor by affecting cell wall synthesis 
and extracellular DNA release of S. aureus. We further provide evidence that HAM can increase the 
susceptibility of S. aureus biofilms towards different classes of antibiotics in vitro. Finally, we show that 
HAM increases the susceptibility of S. aureus to antibiotic treatment in in vivo Caenorhabditis elegans 
and mouse mammary gland infection models.
Staphylococcus aureus is an important causative agent of acute and chronic bacterial infections in humans and 
animals1. It is the leading cause of nosocomial infections worldwide and can cause a variety of infections, includ-
ing skin and soft tissue infections, endocarditis, osteomyelitis and infections associated with medical devices1. 
Treatment of S. aureus infections has become increasingly challenging due to the rapid emergence and dissem-
ination of methicillin-resistant strains (MRSA)2,3. In addition, S. aureus often reside within biofilms at the site 
of infection4. Biofilms are microbial sessile communities characterized by cells that are attached to a substratum 
or interface or to each other, are embedded in a self-produced matrix of extracellular polymeric substances and 
exhibit an altered phenotype compared to planktonic cells5. Within these biofilms, S. aureus displays enhanced 
resistance to antimicrobial agents6. This may be due to a decreased penetration of antibiotics, a decreased growth 
rate of the biofilm cells and/or a decreased metabolism of bacterial cells in biofilms7. In addition, the presence of 
persister cells and the expression of specific resistance genes in biofilms may contribute to this tolerance8.
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Few novel antibacterial agents have been developed in recent years and their bacteriostatic or bactericidal 
activity results in selective pressure, with antimicrobial resistance as an inevitable consequence of their use9. 
For this reason, innovative antimicrobials with novel targets and modes of action are needed. One alternative 
approach is targeting the bacterial quorum sensing (QS) system. QS is a process by which bacteria produce and 
detect signal molecules and thereby coordinate their behaviour in a cell-density-dependent manner10. S. aureus 
uses at least two different QS systems to regulate their virulence, the agr system and the RAP/TRAP system11. 
Although the precise interplay between the two systems remains unclear, both are reported to alter gene expres-
sion through the control of RNAIII. In addition, S. aureus possesses a functional LuxS enzyme and produces 
AI-2, but does not possess a LuxPQ- or LsrB-type AI-2 receptor12,13. Given the role QS plays in the regulation of 
S. aureus pathogenicity, QS inhibitors (QSI) could be used as antipathogenic agents11,14,15. Several inhibitors tar-
geting the QS system of S. aureus have been described, but their mechanism of action mostly remains unknown11. 
Hamamelitannin (2′ ,5-di-O-galloyl-d-hamamelose; HAM) was previously suggested to block QS through the 
TraP QS system16 and was shown to increase S. aureus biofilm susceptibility towards vancomycin (VAN) although 
mechanistic insights are still lacking17.
In the present study we provide evidence that HAM affects S. aureus biofilm susceptibility through the TraP 
receptor, resulting in altered cell wall synthesis and extracellular DNA (eDNA) release. We further provide evi-
dence that HAM can increase the susceptibility of S. aureus biofilms towards different classes of antibiotics. 
Finally, HAM is capable of increasing the susceptibility of S. aureus towards antibiotics in Caenorhabditis elegans 
and mouse mammary gland infection models.
Results
HAM affects S. aureus susceptibility to various classes of antibiotics. We evaluated the effect of 
HAM on susceptibility of S. aureus towards a wide range of antibiotics. These included cefazolin (CZ), cefalonium 
(CL), cephalexin (CFL), cefoxitin (Cfx), daptomycin (DAP), linezolid (LNZ), tobramycin (TOB) and fusidic acid 
(FA). HAM had no effect on the MIC of these antibiotics against S. aureus Mu50 (Supplementary Table S1). 
Although minor differences in MIC were observed for some antibiotics, these differences were within the accept-
able margin of error and were not considered as relevant. As such FIC indices were ≥ 0.5 for all combinations 
indicating that there was no synergistic activity and that the interactions observed are indifferent. In contrast, 
significantly increased killing of S. aureus Mu50 biofilm cells was observed when CZ, CL, CFL, Cfx, DAP, LNZ 
and TOB were used in combination with HAM (Fig. 1). Increased killing of biofilms cells by antibiotics used in 
combination with HAM was also observed for other S. aureus strains (Supplementary Figure S1).
HAM affects S. aureus biofilm susceptibility by interfering with QS. We evaluated the effect of 
HAM on VAN susceptibility of S. aureus strains with mutations in the QS system (Δ agrA, Δ agrB, Δ agrC, Δ traP 
and Δ luxS). In addition, we evaluated the effect of HAM on VAN susceptibility of S. aureus strains with mutations 
Figure 1. Effect of HAM on biofilm susceptibility of S. aureus Mu50 against different types of antibiotics. 
The percentage CFU/biofilm ± s.d. (compared to untreated control biofilm) for biofilms exposed to vancomycin 
(VAN), cefazolin (CZ), cefalonium (CL), cephalexin (CFL), cefoxitin (Cfx), daptomycin (DAP), linezolid 
(LNZ), tobramycin (TOB) or fusidic acid (FA) alone or in combination with HAM. *significantly increased 
killing was observed when biofilms were treated with the combination of the antibiotic and HAM compared to 
treatment with the antibiotic alone (n ≥ 9; one-way; p < 0.05).
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in other regulatory genes, or in genes known to affect biofilm formation and/or resistance (e.g. Δ sarA, Δ sarU, 
Δ icaA, Δ kpdD, Δ codY). HAM was used in concentrations well below the MIC, had no effect on growth and had 
no effect on the number of metabolically active cells when tested against biofilms formed by the S. aureus mutants 
(Supplementary Figure S2). In contrast, when VAN was used in combination with HAM, the S. aureus JE2 and 
ATCC 49230 wild-type strains became more susceptible to VAN (Fig. 2). However, this increased susceptibility to 
VAN in the presence of HAM disappeared in S. aureus strains lacking a functional agr or traP QS system (Fig. 2). 
In addition, the Δ traP mutant was more susceptible to VAN, even in the absence of HAM. Importantly, the com-
plemented Δ traP mutant strain Δ traP pLI50-U1 traP displayed decreased susceptibility towards VAN alone in 
comparison to the Δ traP mutant strain. In addition, the susceptibility of the complemented strain towards VAN 
was increased when VAN was used in combination with HAM (Fig. 2). Mutations in other genes did not affect the 
activity of HAM (Supplementary Figure S2).
S. aureus strains belong to one of four agr groups depending on the amino acid sequence and length of the 
AIP and the cognate receptor AgrC18. As our results indicate that the agr QS system also plays a role in the activ-
ity of HAM, we evaluated whether HAM was active against S. aureus strains belonging to different agr groups. 
Although HAM had no effect by itself and although the susceptibility of the biofilms of S. aureus strains belong-
ing to different agr groups towards VAN differed, in most cases more biofilm cells were killed when strains were 
treated with a combination of VAN and HAM compared to VAN treatment alone (Fig. 3). However, no increased 
susceptibility was observed for S. aureus NRS149 (agr group II) and S. aureus NRS112 (agr group III) (Fig. 3). 
Although the latter strain is reported to contain a mutation in agr, resulting in an already decreased RNAIII 
Figure 2. Effect of HAM on biofilm susceptibility of S. aureus WT strains, QS mutants and complemented 
strains. Biofilms of S. aureus JE2 WT and QS mutants (a) and S. aureus ATCC 49230, Δ traP mutant and the 
traP complemented strain Δ traP pLI50-U1 traP (b) were exposed to VAN alone (black bars) or a combination 
of HAM and VAN (grey bars). Cell viability was quantified by CTB staining and signals are presented as 
percentages (average ± s.d.) compared to the signal of an untreated biofilm. *significantly different signals were 
observed between both treatments (n ≥ 9; one-way; p < 0.01).
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production, no mutations in the QS system have been reported for S. aureus NRS149. This indicates that HAM is 
active against S. aureus strains with different agr types, although its activity may be strain-dependent.
HAM did not affect susceptibility of closely related Staphylococcus species (Supplementary Figure S3) or that 
of selected Gram negative bacteria (Supplementary Figure S4) indicating that the effect of HAM on biofilm sus-
ceptibility is specific for S. aureus.
HAM affects biofilm susceptibility by affecting peptidoglycan synthesis and cell wall 
thickness. Next, we wanted to elucidate the mechanism by which HAM increases the susceptibility of S. 
aureus biofilm towards VAN. HAM had no effect on growth of S. aureus Mu50, nor did it affect membrane integ-
rity of S. aureus biofilm cells after 10 min or 24 h of incubation (Supplementary Figure S5).
To further pursue the molecular mechanism by which HAM affects biofilm susceptibility towards VAN, we 
compared the transcriptome of treated versus untreated S. aureus Mu50 biofilm cells using RNA sequencing. 
Treatment with either HAM or VAN alone or treatment with a combination of both had a significant impact 
on gene-expression (Fig. 4 and supplementary Figure S6). Between 600 and 800 genes were differentially up- or 
down-regulated after treatment with HAM, VAN or a combination of both (Supplementary Table S2).
Treatment with HAM (either alone or in combination with VAN) resulted in a significant downregulation of 
the traP gene compared to the untreated control (− 1.54 and − 1.84 fold change for HAM and combination of 
VAN and HAM, respectively). Although treatment with HAM resulted in an up-regulation of agrA and agrC (1.56 
Figure 3. Effect of HAM on biofilm susceptibility of S. aureus strains belonging to different agr groups. 
Biofilms were exposed to HAM or VAN alone or a combination of VAN and HAM (COMB). Cell viability was 
quantified by CTB staining and signals are presented as percentages (average ± s.d.) compared to the signal of 
an untreated biofilm. *significantly different signals were observed between cells exposed to VAN alone and 
exposed to a combination of VAN and HAM (n ≥ 9; one-way; p < 0.01).
Figure 4. Number of differentially expressed genes in treated cells compared to untreated cells. Number 
of genes differentially (a) up- or (b) downregulated in S. aureus Mu50 biofilm cells exposed to HAM, VAN or a 
combination of HAM and VAN compared to unexposed cells.
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and 1.69 fold change, respectively), no difference in expression of agr genes was observed with the combination 
treatment.
Not unexpectedly, several genes that were previously reported to be differentially expressed in glycopeptide 
resistant strains or after glycopeptide treatment were differentially expressed after VAN treatment in the present 
study as well (Supplementary Table S3)19–25. An important response mechanism of S. aureus towards glycopep-
tides is an increased cell wall synthesis and increased cell wall thickness26.
To achieve this, S. aureus cells upregulate uptake of building blocks, upregulate peptidoglycan synthesis and 
upregulate the biosynthesis of precursors27. This response was also observed in the VAN treated biofilms and in 
biofilm cells treated with a combination of VAN and HAM (Supplementary Figure S6).
Moreover, SAV1422, encoding a glucose specific enzyme was 1.80 and 3.68 fold upregulated in the presence 
of VAN alone or in combination with HAM. Similarly, several genes including sgtA, sgtB and pbp2-4 which are 
related to cell wall biosynthesis were upregulated in the presence of VAN (either alone or in combination with 
HAM) (Supplementary Figure S6)28. These genes are directly involved in peptidoglycan (precursor) biosynthe-
sis28. This indicates that when VAN is added (alone or in combination with HAM), more glucose will be taken up 
by the cell and synthesis of peptidoglycan will be increased.
Although HAM alone does not change the expression of the above-mentioned genes, several genes involved 
in biosynthesis of precursors of peptidoglycan components are differentially expressed when HAM was used in 
combination with VAN compared to exposure to VAN alone. For example glmS, asd, dapB and dapD were sig-
nificantly downregulated in cells exposed to HAM in combination with VAN while no difference in regulation 
was observed in cells exposed to VAN alone (Supplementary Table S2). In addition, glnA, lysC and dapA were 
upregulated and narH and narG were downregulated in cells exposed to VAN, while no significant change in 
expression were observed in cells exposed to VAN in combination with HAM compared to the untreated cells. 
In addition, several genes were strongly down-regulated in cells treated with a combination of VAN and HAM 
compared to VAN treatment alone, e.g. hutU (− 9.6 compared to − 4.7 fold change), hutI (−12.2 compared to 
− 5.6 fold change), gltD (− 26.1 compared to − 3.4 fold change) and gltB (− 15.4 compared to − 2.6 fold change) 
(supplementary Figure S6). These genes are all involved in biosynthetic pathways leading to the synthesis of pre-
cursors of peptidoglycan and or glutamine consuming pathways.
Combined, these RNA-sequencing data point towards changes in peptidoglycan biosynthesis after treatment 
with VAN alone or VAN in combination with HAM. To confirm these changes, we evaluated the susceptibility 
of biofilm cells treated with HAM, VAN or a combination of VAN and HAM towards lysostaphin and measured 
cell wall thickness by electron microscopy (Fig. 5). The untreated biofilm cells or those treated with HAM were 
sensitive to lysostaphin while biofilm cells receiving a pre-treatment with VAN were much more resistant to lys-
ostaphin treatment (Fig. 5A). In contrast, biofilm cells treated with VAN in combination with HAM displayed a 
significant higher sensitivity towards lysostaphin compared to those treated with VAN alone (Fig. 5A). This sug-
gests that changes in cell wall thickness occur after treatment. In order to obtain direct evidence we evaluated the 
effect of VAN, HAM or a combination of HAM and VAN on cell wall thickness by electron microscopy (Fig. 5B). 
The S. aureus Mu50 biofilm cells treated with VAN had significant thicker cell walls compared to untreated bio-
film cells (Fig. 5B). Although HAM alone did not affect cell wall thickness, significant thinner cell walls were 
measured for cells treated with a combination of VAN and HAM compared to VAN treatment alone (Fig. 5B).
HAM affects biofilm susceptibility by altering the amount of eDNA in the biofilm matrix. Our 
RNA sequencing data also indicated that the lrgAB genes were differentially expressed after treatment. These 
genes were significantly downregulated after treatment with VAN (− 3.09 and − 2.44 fold change, respectively) 
while no difference in expression was observed after combination treatment (Supplementary Table S2). The lrgAB 
genes were previously reported to affect autolysis and eDNA release29. Also, the expression of SAV0913 (encod-
ing the autolysin N-acetylmuramyl-L-alanine amidase), lytM (encoding the glycyl-glycine endopeptidase) and 
SAV1051 (encoding the autolysin transcription regulator) differed between treatment with VAN alone or in com-
bination with HAM (Supplementary Table S2). This led us to the hypothesis that HAM alters the amount of 
eDNA in the biofilm matrix and thereby alters susceptibility of the biofilm. To confirm this hypothesis we eval-
uated the amount of eDNA in S. aureus biofilms formed in the presence of HAM (Fig. 6A). In addition, we eval-
uated whether exposure to HAM would alter eDNA concentrations in an already established biofilm (Fig. 6B). 
Less eDNA was present in the matrix under both conditions indicating that HAM indeed alters the amount of 
eDNA present in the biofilm. Also, significantly less eDNA was present in biofilms exposed to a combination of 
VAN and HAM (Fig. 6B). To confirm the role of eDNA in biofilm susceptibility, we evaluated the effect of DNAse 
pre-treatment on susceptibility toward VAN. Significantly less metabolically active cells were present in VAN 
treated biofilms when these biofilms were pre-treated with DNase (reduction of 30.4 ± 9.8% and 76.3 ± 6.2% 
compared to the untreated control after VAN treatment of biofilm receiving no pre-treatment or a pre-treatment 
with DNase, respectively) (Fig. 6C). In addition, a significant reduction in metabolically active cells was also 
observed when the combination treatment was preceded by DNase treatment (reduction of 73.1 ± 3.7% and 
89.4 ± 1.1% after combination treatment of biofilms receiving no pre-treatment or a pre-treatment with DNase, 
respectively) (Fig. 6C).
Finally, to confirm that TraP is the target of HAM, we measured the amount of eDNA present in a S. aureus 
ATCC 49230 Δ traP mutant and evaluated whether HAM altered eDNA production in this mutant. Significantly 
less eDNA was present in the biofilm matrix of the Δ traP mutant strain compared to the WT strain (Fig. 6D). No 
difference in the amount of eDNA was observed when Δ traP mutants formed biofilms in the presence of HAM 
(Fig. 6D). Similar results were also obtained for the S. aureus JE ∆traP mutant strain (data not shown). In addition, 
eDNA production of the complemented strain was increased compared to the Δ traP mutant when no HAM was 
used and eDNA production were reduced to the levels of eDNA production of the Δ traP mutant when HAM was 
present during biofilm formation. This suggests that HAM exerts this effect on eDNA production by interfering 
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with the TraP receptor. Interestingly, although no difference in eDNA was observed between WT and Δ agrA 
biofilms, more eDNA was present in the Δ agrB and Δ agrC mutant compared to the WT strain (2.66 ± 0.58, 
3.21 ± 0.75 and 1.20 ± 0.21 μ g eDNA/ml/108 CFU, for Δ agrB, Δ agrC and WT biofilms, respectively).
Although an upregulation of the mecA gene was observed after treatment with HAM, VAN or both, sev-
eral other genes involved in resistance towards different types of antibiotics were observed to be downregu-
lated in biofilms after treatment. These included aadD, fmtC, norA, tcaB, SAV0690 (tetR) and genes encoding 
beta-lactamases (SAV1504 and SAV1815) and multidrug resistance proteins (SAV0726, SAV1761, SAV2462). 
Downregulation of the expression of these genes might, in addition to the above mentioned mechanisms, also 
explain why HAM increases susceptibility towards various classes of antibiotics.
Figure 5. Effect of treatment on lysostaphin susceptibility and thickness of the cell wall. (a) OD590 nm 
(average ± s.d.) after 10 min lysostaphin treatment of S. aureus Mu50 biofilm cells receiving no pre-treatment 
(CTRL) or a pre-treatment with HAM, VAN or a combination of HAM and VAN (COMB). The OD590nm after 
10 min was compared to the OD590 before the addition of lysostaphin (set at 100%).*the percentage OD590 nm 
is significantly different from that of the cells receiving pre-treatment with VAN (n ≥ 6; one-way; p < 0.05).  
(b) Changes in cell wall thickness of S. aureus Mu50 biofilm cells receiving no treatment (CTRL) or a treatment 
with HAM, VAN or a combination of HAM and VAN (COMB). Significant (n ≥ 100 cells; one way; p < 0.001) 
differences in cell wall thickness were observed between the untreated and VAN treated biofilm cells and 
between biofilm cells receiving a treatment with VAN or a combination of VAN and HAM.
www.nature.com/scientificreports/
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HAM represses antibiotic induced increase in bacterial virulence. Our RNA sequencing data 
showed that VAN treatment resulted in an upregulation of several genes encoding enterotoxins (e.g. seg, sen, yent1 
and yent2), exotoxins (set10, set11, set12 and toxic shock toxin tst) and leukocidins/hemolysins (e.g. hlgA, hlgB, 
hlgC and SAV1163) (Fig. 7A). An increase in virulence gene expression as a response to antibiotics was previously 
also observed in other studies30–32. In contrast, when VAN was used in combination with HAM, no upregulation 
was observed for most of these genes (Fig. 7A). In addition, although an upregulation was observed for sec3, hlgC 
and SAV1163 in cells treated with a combination of VAN and HAM (fold change of 1.67, 2.11 and 1.90 compared 
to no treatment, respectively), this upregulation was significantly lower than the upregulation observed in cells 
treated with VAN alone (fold change of 2.38, 5.96 and 4.05 compared to vehicle control, respectively) (Fig. 7A). 
In line with these observations we also observed reduced α -hemolysin activity in supernatants of S. aureus Mu50 
biofilms treated with HAM, while an increased hemolytic activity was observed for biofilms treated with VAN 
(Fig. 7B). In contrast, the supernatant of biofilm cells treated with a combination of VAN and HAM showed 
significantly reduced hemolytic activity (absorbance of 0.22 ± 0.06, 2.47 ± 0.42 and 0.67 ± 0.24 for supernatants 
from biofilms treated with a combination of VAN and HAM, VAN alone or untreated cells) (Fig. 7B).
HAM affects biofilm susceptibility and virulence in vivo in C. elegans and in mouse mammary 
gland infection models. Although treatment with HAM and VAN alone resulted in an increased survival 
of infected C. elegans nematodes (Supplementary Figure S7), either HAM or VAN alone had no effect on the 
number of bacteria present in C. elegans nematodes after 24 h of infection (Fig. 8A). In contrast, significantly less 
CFU/nematode were present when a combination of HAM and VAN was used to treat the infected nematodes 
(Fig. 8A). In addition, a significant higher percentage of C. elegans nematodes survived infection after treatment 
with a combination of HAM and VAN compared to treatment with VAN alone (Supplementary Figure S7).
Next, we evaluated the effect of HAM on S. aureus susceptibility in an established murine mammary 
gland infection model with the bovine mastitis isolate S. aureus Newbould 30533. Bovine mastitis caused by 
Staphylococci is typically treated with cephalosporins and as such CFL was used33.
As for C. elegans, HAM itself had no effect on the number of CFU present in the infected mouse mammary 
glands (Fig. 8B). Although treatment with CFL resulted in a decrease in the number of CFU/g mammary gland 
when used alone, significantly less CFU was present after treatment with CFL in combination with HAM (Fig. 8B). 
Macroscopical signs of inflammation were mainly observed in the glands of mice receiving no treatment and to 
Figure 6. HAM alters the amount of eDNA in the biofilm and thereby affects biofilm susceptibility.  
(a) The amount of eDNA (average ± s.d.) present in S. aureus Mu50 biofilms formed in the absence (CTRL) 
or presence of HAM. (b) The amount of eDNA (average ± s.d.) in 24 h old biofilms receiving no treatment 
(CTRL) or a treatment with HAM or VAN alone or a combination of VAN and HAM (COMB). (c) Cell viability 
as quantified by CTB staining for S. aureus Mu50 biofilms receiving no pre-treatment, or a pre-treatment 
with DNase followed by (i) no treatment (CTRL), (ii) a treatment with VAN or (iii) a combination of VAN 
and HAM (COMB). CTB signals are presented as percentages (average ± s.d.) compared to the signal of an 
untreated biofilm. (d) The amount of eDNA (average ± s.d.) present in biofilms of S. aureus ATCC 49230, Δ traP 
mutant and the traP complemented strain Δ traP pLI50-U1 traP formed in the absence (CTRL) or presence 
of HAM. *indicates significant (p < 0.05) differences between the amount of eDNA present in the treated 
biofilms compared to the CTRL biofilm (a,b,d) or in % signal compared to the biofilms treated with VAN 
(c). **significant (p < 0.05) differences in percentage signal are observed between biofilm cells treated with a 
combination of VAN and HAM following no pre-treatment or a pre-treatment with DNase.
www.nature.com/scientificreports/
8Scientific RepoRts | 6:20321 | DOI: 10.1038/srep20321
a much lesser extent in the glands of mice receiving a treatment with HAM or CFL (Supplementary Figure S8). 
In addition, an influx of neutrophils was observed in the alveoli of the glands in the untreated conditions or the 
mice receiving treatment with HAM alone (Fig. 8C). This innate immune response was not observed in the mice 
receiving treatment with CFL or a combination of CFL and HAM (Fig. 8C).
Discussion
HAM was discovered via virtual screening of a library of small molecules using a pharmacophore model based 
on RNAIII inhibiting peptide (RIP), a peptide that blocks QS in S. aureus16. It was therefore suggested that HAM 
also blocks QS through the TraP QS system16. However, its target was never validated and as such it is still unclear 
Figure 7. Effect of treatment on expression of virulence genes and hemolytic activity. (a) Fold changes 
in expression of selection of virulence genes in S. aureus Mu50 biofilms treated with VAN (black bars) or a 
combination of VAN and HAM (grey bars) compared to expression in untreated biofilm cells. *significant 
(p < 0.01) differences are observed in gene expression between biofilm cells treated with VAN or a combination 
of VAN and HAM. (b) OD420 nm (average ± s.e.m.) (as indication of hemolytic activity) of rabbit blood 
incubated with the supernatant of S. aureus Mu50 untreated biofilm cells (CTRL) or biofilm cells treated 
with HAM or VAN alone or a combination of VAN and HAM (COMB). *significant (p < 0.01) differences in 
OD420 nm between biofilm cells treated with VAN or a combination of VAN and HAM and between untreated 
biofilms and HAM treated biofilms.
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whether HAM truly affects QS through the TraP receptor. In addition, although HAM was shown to increase S. 
aureus biofilm susceptibility towards vancomycin17, several questions remained unanswered: how does HAM 
affect S. aureus susceptibility at the molecular level? Does this effect also occur in other closely or unrelated 
species and with other antibiotics? Finally, the potential clinical application of HAM had not been evaluated in 
relevant in vivo models of S. aureus infection.
First, we investigated the spectrum of HAM. Our results show that HAM increases the susceptibility of S. 
aureus biofilms to different classes of antibiotics, indicating that the effect of HAM is not limited to combinations 
with VAN alone. Although HAM was previously shown to affect attachment and biofilm formation of S. epider-
midis and Acinetobacter baumanii34–36 our result show that HAM only affected susceptibility of S. aureus and not 
that of unrelated Gram negative or more closely related Gram positive bacteria.
Secondly, we addressed the specificity of HAM for the TraP receptor in the S. aureus QS system employing two 
strategies. First we evaluated the effect of HAM on the susceptibility of biofilms of S. aureus strains with mutations 
in genes directly involved in the QS systems or in genes involved in biofilm formation and virulence. Secondly, we 
identified genes that were differentially expressed upon treatment, using RNA sequencing. HAM had no effect on 
biofilm susceptibility of S. aureus QS mutants while the effect was maintained for strains with mutations in other 
genes. This indicates that HAM truly affects biofilm susceptibility through the S. aureus QS system. Although our 
results suggest that the agr QS system is also involved in this mechanism of action, we do believe that the TraP 
receptor might be the first target of HAM for several reasons. First, no additional effect on biofilm susceptibility 
is observed for the combination therapy in agr mutant strains, while these agr mutants are as susceptible towards 
VAN as the WT strain. In contrast, the Δ traP mutant is much more susceptible towards VAN. Secondly, we can 
exclude the possibility that AgrC (i.e. the receptor for AIP in the agr QS system) will be the target of HAM since 
HAM exerted its effect in strains belonging to different agr groups. Although this does not exclude the possibility 
that HAM interacts with AgrA, a downstream regulator of the agr QS system we believe this is unlikely. HAM 
fits the pharmacophore model of RIP, a peptide described to block QS by affecting TraP16, while it is structurally 
unrelated to savarin, a specific inhibitor of AgrA37. Thirdly, the traP gene was downregulated in S. aureus Mu50 
treated with HAM alone or in combination with VAN, while expression of agrA and agrC was only affected when 
HAM was used alone. Together, these data indicate that HAM affects biofilm susceptibility through TraP.
Next, we addressed the question on how HAM resulted in an increased susceptibility towards antibiotics. S. 
aureus Mu50 does not contain the vanAB genes that play a role in VAN resistance in enterococci, but multiple 
genes contribute to glycopeptide resistance in this (and other) S. aureus strain26,27. Our combined data indicate 
that HAM affects a set of genes leading to changes in cell wall thickness and amount of eDNA in the biofilm 
matrix.
The molecular mechanism behind the increased cell wall thickness is the lower expression of several genes 
involved in the biosynthesis of peptidoglycan precursors such as e.g. glmS, lysC, asd, dapA in the presence of a 
combination of VAN and HAM, compared to exposure to VAN alone. GlmS and enzymes encoded by the dap 
Figure 8. Effect of treatment on in vivo susceptibility of S. aureus. (a) Log CFU/nematode (average ± s.d.) 
in C. elegans nematodes infected with S. aureus Mu50 or Newbould 305, receiving no treatment or a 
treatment with HAM, VAN or a combination of VAN and HAM (COMB). (b) Log CFU/g mammary gland 
(average ± s.d.) of mice infected with S. aureus Newbould305 receiving no treatment or a treatment with HAM, 
CFL or a combination of CFL and HAM (COMB). (c) Histological evaluation of mammary glands of mice 
infected with S. aureus Newbould305 receiving no treatment or a treatment with HAM, CFL or a combination 
of CFL and HAM (COMB). Arrows indicate influx of neutrophils. *significant differences in log CFU/nematode 
(a) or log CFU/g mammary gland (b) between the indicated samples (p < 0.01).
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operon play a role in the production of GlcN-6-P and in the conversion of L-aspartate to L-lysine, respectively. 
Both GlcN-6-P and L-lysine are important components of the cell wall. In addition, the expression of genes 
belonging to pathways leading to L-glutamate production (from L-histidine or α -ketoglutarate), to the glutamine 
consuming pyrimidine pathway, and genes from the nas operon were also differentially expressed in the presence 
of a combination of VAN and HAM, compared to exposure to VAN alone. Combined, these differences are likely 
to result in depletion of glutamine during VAN treatment, a depletion that will not be observed when VAN is 
combined with HAM, and this glutamine depletion can affect susceptibility of S. aureus towards VAN27.
Although genes involved in final stages of peptidoglycan synthesis are also upregulated in S. aureus Mu50 
biofilm cells exposed to a combination of VAN and HAM (including sgtA, sgtB and pbp2-4), this will not lead 
to increased cell wall thickness as HAM will prevent S. aureus cells from increasing the required peptidoglycan 
precursor synthesis.
Our results further indicate that the release of eDNA plays an important role in the mechanisms of action of 
HAM. Significantly less eDNA was present in the biofilm matrix of biofilms treated with HAM or in the Δ traP 
mutant, and HAM had no effect on the amount of eDNA in the matrix of the biofilm of the Δ traP mutant. These 
changes could also be complemented. Removal of eDNA had a significant impact on biofilm susceptibility indi-
cating that changes in eDNA as a consequence of HAM-treatment will affect biofilm susceptibility. This is in 
agreement with the observation that eDNA is a major structural adhesin in S. aureus biofilms38–40 and that eDNA 
can directly bind VAN thereby trapping it before it can reach the cell41.
Both the increased cell wall thickness and presence of eDNA lead to trapping of more VAN, decreasing the 
VAN diffusion constant and eventually decreasing susceptibility towards VAN27. HAM affects both response 
mechanisms, thereby making S. aureus more susceptible to antibiotic treatment. Changes in peptidoglycan struc-
ture and the amount of eDNA in the biofilm matrix are likely to also affect the susceptibility towards other antibi-
otics including but not limited to β -lactam antibiotics and daptomycin41–43 and this was confirmed in the present 
study.
Although QS systems are activated and QS-regulated phenotypes are apparent in vitro (in the absence of a 
host), it is unclear whether QS requires a host to be fully activated. QS-based regulation of different phenotypes 
depends on the environment in which the bacteria reside, and in addition, many chemical compounds, such as 
QS inhibitors are prone to chemical changes or degradation under in vivo conditions, thereby making them less 
active. This indicates that the host can play a role in the way the QS system is activated and in whether the com-
pound displays in vivo activity (or not). For this reason, we evaluated the effect of HAM on S. aureus susceptibility 
in a murine model of S. aureus mastitis infection. S. aureus is one of the most important etiological agents of sub-
clinical and clinical mastitis44,45. In addition, once established, S. aureus infections are extremely hard to eradicate 
from the mammary gland33. We show that although HAM by itself did not result in a significant decrease in cell 
numbers, HAM increases susceptibility of S. aureus towards CFL in a murine model of mastitis infection.
Altogether our findings demonstrate that HAM interferes with QS in S. aureus and thereby increases sus-
ceptibility of S. aureus biofilms to various antibiotics. Data from animal experiments suggest that HAM has the 
potential to increase the effect of antibiotics in vivo and could be used in combination treatment schemes.
Materials and Methods
Reagents used. Hamamelitannin (HAM), vancomycin (VAN), cefoxitin (CFX), cefazolin (CZ), cefalonium 
(CL), cephalexin (CFL), linezolid (LNZ) and fusidic acid (FA) were purchased from Sigma Aldrich (Bornem, 
Belgium). Tobramycin (TOB) and daptomycin (DAP) were purchased from TCI (Tokyo, Japan). HAM was stored 
in DMSO at − 20 °C. All antibiotics were dissolved in ultrapure water (with the exception of CZ, CL and CFL, 
which were dissolved in phosphate buffer). HAM was used at 250 μ M concentrations unless otherwise mentioned.
Bacterial strains and growth conditions. The following strains were used as previously described: 
methicillin-resistant Staphylococcus aureus Mu50 (MRSA Mu50), Pseudomonas aeruginosa PAO1, Burkholderia 
cenocepacia LMG1665617, Staphylococcus capitis ET005, Staphylococcus caprae NW003, Staphylococcus cohnii 
ET027, Staphylococcus chromogenes NW110, Staphylococcus epidermidis ET013 and ET041, Staphylococcus 
haemolyticus ET070, Staphylococcus hyicus ET053, Staphylococcus hominis ET056, Staphylococcus lentus ET004, 
Staphylococcus lugdunensis NW045, Staphylococcus saprophyticus ET094, Staphylococcus pasteuri ET054, 
Staphylococcus schleiferi NW139, Staphylococcus warneri ET019 and Staphylococcus xylosus ET01846, and 
S. aureus Newbould 305 (ATCC 29740)33. S. aureus NRS384 (agr I), NRS149 (agr II), NRS123 (agr III), NRS112 
(agr III), NRS153 (agr IV), JE2 (MRSA USA300; agr I) and transposon mutants NE1532 (Δ agrA), NE95 (Δ agrB), 
NE873 (Δ agrC), NE294 (Δ traP), NE1746 (Δ luxS), NE423 (Δ kdpD), NE1249 (Δ kdpE), NE1193 (Δ sarA), NE96 
(Δ sarU), NE1555 (Δ codY), NE1474 (Δ cshA), NE1241 (Δ nuc), NE37 (Δ icaA) and NE13 (Δ rbsU) were obtained 
through the Network on Antimicrobial Resistance in Staphylococcus (NARSA) (distributed by BEI Resources, 
NIAID, NIH). S. aureus ATCC 49230, Δ traP mutant and the traP complemented strain Δ traP pLI50-U1 traP 
were kindly provided by Dr. Smeltzer and Dr. Beenken47. All strains were cultured in Mueller-Hinton broth (MH, 
Oxoid, Basingstoke, England) at 37 °C under aerobic conditions. All mutants were grown in the presence of 
appropriate amounts of erythromycin.
Determination of the MIC of HAM and effect of HAM on growth. MICs of HAM against the dif-
ferent strains used were determined in triplicate using flat-bottom 96-well microtiter plates (TPP, Trasadingen, 
Switzerland) as previously described17. If the MIC determined in both conditions differed, checkerboard test-
ing48 was performed to determine whether the interaction is synergistic (fractional inhibitory concentration 
[FIC] index ≤ 0.5) or indifferent (FIC index > 0.5). In addition, the effect on growth was investigated as follows. 
Overnight cultures of the different strains were diluted to approximately 5 × 107 colony-forming units (CFU)/ml 
in MH. Ten μ l of this suspension was added to the wells of a 24-well microtiter plate and mixed with 990 μ l MH 
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:20321 | DOI: 10.1038/srep20321
(in the presence or absence of HAM). Plates were incubated at 37 °C and the OD590 nm was measured every 30 min 
for 24 h. Three wells were included per condition and the experiment carried out in duplicate (n = 2 × 3).
Biofilm formation and treatment of the biofilm. S. aureus Mu50 biofilms were formed as pre-
viously described17. In brief, overnight cultures in MH were centrifuged, the pellet was resuspended in 
double-concentrated MH (2 × MH) and diluted to an OD590 nm of 0.2. Fifty microliter of the diluted bacterial 
suspension was transferred to the wells of a round-bottom 96-well microtiter plate (TPP). Control wells received 
50 μ l MilliQ. Wells used to evaluate pre-treatment received 50 μ l of HAM solution (250 μ M final concentration). 
Bacteria were allowed to adhere and grow without agitation for 4 h at 37 °C. After 4 h, medium was removed, and 
the adhered cells were washed with sterile physiological saline (0.9% NaCl; PS). After this washing step, control 
wells were filled with 50 μ l 2 × MH and 50 μ l MilliQ. Other wells were filled with 50 μ l 2 × MH and 50 μ l of HAM, 
and the plate was incubated for 20 h at 37 °C. To evaluate the effect of co-treatment on mature biofilms, control 
biofilms were formed in the absence of HAM, as described above. After 24 h of biofilm formation, the medium 
was removed and the wells were rinsed with PS. Control wells were either filled with 100 μ l PS (untreated con-
trols) or with 50 μ l PS and 50 μ l antibiotic solution. Wells used to evaluate the effect of pre-treatment were also 
filled with 50 μ l PS and 50 μ l antibiotic solution while wells used to evaluate combination treatment were filled 
with 50 μ l of a HAM solution (250 μ M final concentration) and 50 μ l antibiotic solution. The plates were then 
incubated for an additional 24 h at 37 °C. After biofilm formation and treatment of the biofilms, the number 
of metabolically active cells were determined by resazurine staining (cell-titer blue, CTB)49 or by conventional 
plating17. To collect the cells for plating, plates were rinsed with PS, sessile cells were removed from the microtiter 
plate by two cycles of vortexing (5 min) and sonication (5 min) and the number of CFU/biofilm was determined 
by plating the resulting suspensions. The number of CFU/biofilm (for plating) or the fluorescence signal (for CTB 
staining) of the control biofilms was set to 100% and the results of the treated biofilms were compared to this. 
Each condition was tested in at least three wells in each assay, and each assay was carried out at least in triplicate 
(n ≥ 9).
RNA-sequencing and data-analysis. Gene expression was measured in biofilms receiving no treatment, 
a treatment with VAN or HAM alone or a combination of VAN and HAM. For each condition 3 independent 
samples were incubated. RNA was extracted and approximately 30 ng of rRNA depleted RNA was used to create 
barcoded strand specific libraries with the Truseq stranded library preparation kit (Illumina, San Diego, USA). 
The libraries were equimolarly pooled and sequenced using an Illumina HiSeq 2000, generating 100 bp unpaired 
reads. After sequencing, the data were demultiplexed using sample specific nucleotide sequence thereby generat-
ing .fastq-files. The fastq-files were deposited in arrayexpress database (http://www.ebi.ac.uk/arrayexpress/) and 
are under the accession number: E-MTAB-3816.
After initial quality control, at least 10,000,000 high quality filtered reads were included in the analysis. Reads 
for each condition were mapped to the S. aureus Mu50 genome50. In order to be included in the analysis, reads 
must map to the entire gene with 100% similarity. In addition to these stringent mapping conditions, no mapping 
to the flanking regions is allowed. The number of reads assigned to a transcript were divided by the transcript 
length and normalized to the number of mapped reads to obtain reads per kb per million (RPKM) expression 
values.
Statistical analyses were performed using Baggerley’s t-test in the CLC genomics workbench software51. 
Statistical significance was defined as a p value smaller than 0.05. Only genes that were significantly differentially 
regulated (p < 0.05) and whose regulation differed at least 1.5 fold compared to the control were considered.
Effect of HAM on membrane integrity. Membrane integrity was measured using propidium iodide as 
described37,52. S. aureus Mu50 was cultured overnight (16 h) in MH, centrifuged and the pellet was resuspended 
in PBS. The suspension was diluted to an OD600nm of 0.4. One ml aliquots received no treatment or were exposed 
to HAM and were placed at 37 °C for 10 min or 24 h. Heat killed cells (90 °C for 10 min) served as positive con-
trol. After 10 min or 24 h of treatment, propidium iodide was added for an additional 15 min to the samples and 
membrane damage was determined by measuring bacterial fluorescence (ex:485 nm; em:635 nm) by Envision 
microtiter plate reader (Perkin Elmer).
Effect of HAM on lysostaphin susceptibility. Biofilms were formed and treated as described above. Cells 
were collected, resuspended and standardized to OD600nm of 0.5. Lysostaphin (10 μ g/ml) was added to the sus-
pension and lysis was measured as a decrease in OD620nm during incubation at 37 °C using an Envision microtiter 
plate reader (Perkin Elmer).
Electron microscopy. Biofilms of S. aureus Mu50 strains were formed and treated as described above. After 
biofilm formation and treatment, biofilm cells were collected, washed and examined by transmission electron 
microscopy as previously described53. Morphometric evaluation of cell wall thickness was performed by using 
photographs of images obtained at a final magnification of 330,000. The thickness of the cell wall of at least 100 
cells, in each condition, with nearly equatorially cut surfaces were measured using ImageJ software (http://imagej.
nih.gov/ij/).
Quantification of eDNA in the biofilm matrix. eDNA was quantified as previously described54, with 
minor modifications. In brief, biofilms were formed in the absence and presence of HAM as described above. 
Biofilm cells were washed and collected in Eppendorf protein LoBind microcentrifuge tubes (1.5 mL)
(Eppendorf AG, Hamburg, Germany). The biofilm cells were separated from the matrix by centrifugation 
at 5000 g for 10 min at 4 °C. The supernatant was aspirated and filtered through a 0.2 μ m cellulose acetate filter 
(Whatman GmbH, Dassel, Germany) and the amount of eDNA was quantified using the Quantifluor dsDNA 
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System kit (Promega, Madison, WI, USA). eDNA concentrations were normalized to the number of biofilm cells, 
determined by plate counting after 24 h of biofilm growth.
Effect of DNAse on vancomycin susceptibility. Biofilms were formed in the absence and presence of 
HAM as described above. After 24 h of biofilm formation, biofilms were washed and a DNase solution (100 μ g/ml) 
was added for 30 min. After this, the DNase solution was removed, cells were washed, a treatment with VAN was 
added and the cells were incubated for 24 h at 37 °C. After 24 h, treatment was removed, the biofilm cells were 
washed and the number of metabolically active cells was quantified using CTB staining49.
Effect of exposure to VAN alone or in combination with HAM on hemolytic activity of 
S. aureus. Biofilm were formed and treated with HAM, VAN or a combination of VAN and HAM as described 
above. After 24 h of treatment, biofilms were washed with PBS, cells were collected and standardized to OD600nm 
of 0.4. Two-hundred μ l of each sample was incubated with 800 μ L of 4% rabbit blood (Biotrading, Mijdrecht, 
The Netherlands). Samples treated with 10% SDS or PBS served as controls. All samples were incubated for 24 h 
at 37 °C. After incubation, samples were centrifuged (2 min at 1000 rpm), 100 μ L of the supernatant was spotted 
on a microtiter plate and the OD420nm was measured using the Envision microtiter plate reader (Perkin Elmer).
C. elegans infection assay. C. elegans N2 (glp-4; sek-1) was propagated under standard conditions, syn-
chronized by hypochlorite bleaching, and cultured on nematode growth medium using E. coli OP50 as food 
source as described previously17. The C. elegans assay was carried out as followed. Synchronized worms (L4 
stage) were suspended in a medium containing 95% M9 buffer (3 g of KH2PO4, 6 g of Na2HPO4, 5 g of NaCl, and 
1 ml of 1 M MgSO4 7H2O in 1 liter of water), 5% brain heart infusion broth (Oxoid), and 10 μ g of cholesterol 
(Sigma-Aldrich) per ml. Twenty-five μ l of this suspension of nematodes (containing at least 25 nematodes) was 
transferred to the wells of a 96-well flat-bottomed microtiter plate. An overnight bacterial culture was centrifuged, 
resuspended in the assay medium, and standardized to 109 CFU/ml. Next, 25 μ l of this standardized suspension 
was added to each well, while 25 μ l of sterile medium was added to the positive control. HAM (250 μ M final 
concentration), VAN (20 μ g/ml final concentration) or a combination of both was added to the test wells. The 
assay plates were incubated at 25 °C for up to 24 h. After 24 h, nematodes were collected and washed three times 
with M9 buffer supplemented with 1 mM sodium azide to prevent expulsion of the intestinal load and to remove 
surface-attached bacteria. The number of nematodes was then determined microscopically and nematodes were 
lysed in phosphate-buffered saline containing 400 mg 1.0 mm silicon carbide beads (VWR, Leuven, Belgium) and 
mechanically disrupted using a vortex shaker. Subsequently, lysates were serially diluted, plated on trypton soy 
agar supplemented with 7.5% NaCl and incubated at 37 °C. After 24 h, the number of CFU/nematode was deter-
mined. Each treatment was evaluated at least six times.
Ethics Statement. All experiments were approved by the committee on the ethics of animal experiments 
of Faculty of Veterinary Medicine, Ghent University (Permit Number: EC2013/166). The animal experiments 
considered by the institutional ethical committee are according to specific Belgian (C-2013/24221) and European 
legislation (Directive 2010/63/EU of the European Parliament and of the Council on the protection of animals 
used for scientific purposes).
S. aureus murine intramammary mastitis infection model. The in vivo effect of treatment with HAM 
alone or a combined treatment with HAM and CFL was evaluated using a murine intramammary S. aureus 
infection model, i.e. a model of S. aureus mastitis infection33. In brief, CD-1 dams (Harlan Laboratories Inc., 
Netherlands) were utilized 12–14 days after birth of the offspring. All inoculations were performed two hours 
post weaning under anesthesia. A mixture of oxygen and isoflurane (2–3%) was used for inhalational anesthesia 
of the lactating mice combined with a long-acting analgesic buprenorphine (10 μ g/kg Vetergesic, Patheon UK 
Ltd, Swindon, UK). A syringe with 32-gauge blunt needle (Thiebaud Biomedical Devices, France) was applied to 
inoculate both L4 (on the left) and R4 (on the right) glands of the fourth abdominal mammary gland pair with 
approximately 150 CFU of S. aureus Newbould 305. Each orifice was exposed by a small cut at the near end of the 
teat and 100 μ l of the inoculum was injected slowly through the teat canal. CFL was used as a preferred antibiotic 
in the field to treat mastitis infections in cattle33. In addition, a concentration of 100 μ g/gland CFL was chosen 
since this concentration gave rise to a reduction in CFU/gland without full eradication. This allows observing 
additional killing for the combination, if present. The formulations containing HAM, CFL or a combination of 
CFL and HAM were instilled into the mammary gland of anesthetized mice using the desired dose (μ g/gland) 
at 4 h after bacterial inoculation. All groups were composed of 5 mice (10 mammary glands). All mice were first 
sedated by administering a mixture of ketamine (100 mg/kg Anesketin, Eurovet Animal Health BV, Bladel, The 
Netherlands) with xylazine (10 mg/kg; Xylazini Hydrochloridum, Val d’Hony-Verdifarm, Beringen, Belgium) 
intraperitoneally and subsequently euthanized by cervical dislocation at 14 h post-treatment. The mammary 
glands (two per mouse) were harvested, weighed and homogenized on ice in sterile PBS using a tissue ruptor 
(QIAGEN Benelux BV, Netherlands). The mammary glands, which are physiologically separated, were considered 
as individual samples. Bacterial CFU counts were obtained by standard plating on trypton soy agar supplemented 
with 7.5% NaCl. Histological examination was conducted as previously described55,56.
Statistical evaluation. The normal distribution of the data was checked by using the Shapiro-Wilk test. 
Normally distributed data were analyzed using a one-way ANOVA. Non-normally distributed data were analyzed 
using the Kruskal-Wallis test. Statistics were determined using SPSS software, version 22.0.
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